Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma

Sara Beygi, George E. Duran, Sebastian Fernandez-Pol, Alain H. Rook, Youn H. Kim, Michael S. Khodadoust

Blood (2022) 139 (26): 3732–3736.

https://doi.org/10.1182/blood.2021014468

Published: 2022

Journal Articles

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-136860

Published: 2020

Journal Articles

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study

Blood (2017) 130 (Supplement 1): 817.

https://doi.org/10.1182/blood.V130.Suppl_1.817.817

Published: 2017

Journal Articles

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)

Youn H Kim, MD, Richard T. Hoppe, MD, Alain H Rook, MD, Amit Maity, MD PhD, Larisa J Geskin, MD, David P Horowitz, MD, Genet Finnegan, MHS, PA-C, Michael Khodadoust, MD PhD, Wen-Kai Weng, MD PhD, Analuisa Lares, ANP, BSN, RN, Eric Ki Jun Hong, BS, Marie Buchanan, RN, Vernon Ma, BS, Hue Kha, BS, Chris E Lawrence, PhD, Vladimir Vainstein, MD, Lena A Basile, PhD JD

Blood (2016) 128 (22): 4165.

https://doi.org/10.1182/blood.V128.22.4165.4165

Published: 2016

Journal Articles

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study

Blood (2016) 128 (22): 181.

https://doi.org/10.1182/blood.V128.22.181.181

Published: 2016

Journal Articles

Unique Characteristics of Classical Hodgkin Lymphoma in Patients with Cutaneous T-Cell Lymphoma

Lauren E. Strelec, BA, Erin Haley, MD, Ellen J. Kim, MD, Alain H. Rook, MD, Nirav N. Shah, MD, Anthony R. Mato, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2015) 126 (23): 5003.

https://doi.org/10.1182/blood.V126.23.5003.5003

Published: 2015

Journal Articles

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Alain H. Rook, Joel M. Gelfand, Maria Wysocka, Andrea B. Troxel, Bernice Benoit, Christian Surber, Rosalie Elenitsas, Marie A. Buchanan, Deborah S. Leahy, Rei Watanabe, Ilan R. Kirsch, Ellen J. Kim, Rachael A. Clark

Blood (2015) 126 (12): 1452–1461.

https://doi.org/10.1182/blood-2015-02-630335

Published: 2015

Includes: Supplemental data

Journal Articles

Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study

Madeleine Duvic, MD, Youn H Kim, MD, Alain H Rook, MD, Adam Lerner, MD, Tadeusz Robak, MD, Alexey Samtsov, MD PhD, William McCulloch, M.B., FRCO, FFPM, Joel Waksman, PhD, Sean Whittaker

Blood (2014) 124 (21): 4451.

https://doi.org/10.1182/blood.V124.21.4451.4451

Published: 2014

Journal Articles

The beauty of TLR agonists for CTCL

Alain H. Rook

Blood (2012) 119 (2): 321–322.

https://doi.org/10.1182/blood-2011-11-391243

Published: 2012

Journal Articles

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Vikram R Paralkar, MD, Sunita Dwivedy Nasta, MD, Kelly Morrissey, MD, Jacqueline Smith, MSN, CRNP, Pavel Vassilev, BS, Mary Ellen Martin, MD, Steven C Goldstein, MD, Alison Loren, MD, MPH, Alain H Rook, MD, Ellen J Kim, MD, David L Porter, MD

Blood (2010) 116 (21): 4574.

https://doi.org/10.1182/blood.V116.21.4574.4574

Published: 2010

Journal Articles

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.

Youn H Kim, MD, Marie-France Demierre, MD, Ellen J Kim, MD, Alain H Rook, MD, Adam Lerner, MD, Madeleine Duvic, MD, Sunil Reddy, MD, Tadeusz Robak, MD, PhD, Jürgen C Becker, MD, Alexey Samtsov, MD, William McCulloch, MB, FRCP, Sean Whittaker, MD, FRCP

Blood (2009) 114 (22): 2683.

https://doi.org/10.1182/blood.V114.22.2683.2683

Published: 2009

Journal Articles

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Youn Kim, MD, Sean Whittaker, MD, FRCP, Marie France Demierre, MD, Alain H Rook, MD, Adam Lerner, MD, Madeleine Duvic, MD, Sunil Reddy, MD, Ellen J Kim, MD, Tadeusz Robak, MD, Jürgen C Becker, MD, Alexey Samtsov, MD, William McCulloch, MB, FRCP, Archibald G Prentice, MBChB, FRCP, FRCPath

Blood (2008) 112 (11): 263.

https://doi.org/10.1182/blood.V112.11.263.263

Published: 2008

Journal Articles

Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-α receptor

Julie H. Lin, Ellen J. Kim, Anand Bansal, John Seykora, Stephen K. Richardson, Xian-Yuan Cha, Sarosh Zafar, Sunita Nasta, Maria Wysocka, Bernice Benoit, Alain H. Rook, Steven S. Fakharzadeh

Blood (2008) 112 (6): 2484–2488.

https://doi.org/10.1182/blood-2008-03-141424

Published: 2008

Journal Articles

Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sézary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression

Emmanuel Contassot, Katrin Kerl, Stéphanie Roques, Ryan Shane, Olivier Gaide, Marc Dupuis, Alain H. Rook, Lars E. French

Blood (2008) 111 (9): 4780–4787.

https://doi.org/10.1182/blood-2007-08-109074

Published: 2008

Journal Articles

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

Youn H. Kim, MD, Sunil Reddy, MD, Ellen J. Kim, MD, Alain H. Rook, MD, Adam Lerner, MD, Mariefrance Demierre, MD, Madeleine Duvic, MD, Sean Whittaker, MD, FRCP, Tadeusz Robak, MD, Jurgen C. Becker, MD, William McCulloch, MB, FRCP, Archibald G. Prentice, MB, FRCP, FRCPath, on behalf of All Investigators

Blood (2007) 110 (11): 123.

https://doi.org/10.1182/blood.V110.11.123.123

Published: 2007

Journal Articles

How low can you go: quality effects of an anti-CD4 antibody

Ellen J. Kim, Alain H. Rook

Blood (2007) 109 (11): 4594–4595.

https://doi.org/10.1182/blood-2007-03-079426

Published: 2007

Journal Articles

Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy

Michael Nebozhyn, Andrey Loboda, Laszlo Kari, Alain H. Rook, Eric C. Vonderheid, Stuart Lessin, Carole Berger, Richard Edelson, Calen Nichols, Malik Yousef, Lalitha Gudipati, Meiling Shang, Michael K. Showe, Louise C. Showe

Blood (2006) 107 (8): 3189–3196.

https://doi.org/10.1182/blood-2005-07-2813

Published: 2006

Includes: Supplemental data

Journal Articles

Impaired CD40L signaling is a cause of defective IL-12 and TNF-α production in Sézary syndrome: circumvention by hexameric soluble CD40L

Lars E. French, Bertrand Huard, Maria Wysocka, Ryan Shane, Emmanuel Contassot, Jean-François Arrighi, Vincent Piguet, Silvio Calderara, Alain H. Rook

Blood (2005) 105 (1): 219–225.

https://doi.org/10.1182/blood-2004-03-1055

Published: 2005

Journal Articles

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15

Maria Wysocka, Bernice M. Benoit, Sarah Newton, Livio Azzoni, Luis J. Montaner, Alain H. Rook

Blood (2004) 104 (13): 4142–4149.

https://doi.org/10.1182/blood-2004-03-1190

Published: 2004

Journal Articles

Where have all the T cells gone?

Alain H. Rook, Maria Wysocka

Blood (2003) 102 (12): 3859–3860.

https://doi.org/10.1182/blood-2003-09-3228

Published: 2003

NARROW

Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study

Unique Characteristics of Classical Hodgkin Lymphoma in Patients with Cutaneous T-Cell Lymphoma

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study

The beauty of TLR agonists for CTCL

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-α receptor

Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sézary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

How low can you go: quality effects of an anti-CD4 antibody

Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy

Impaired CD40L signaling is a cause of defective IL-12 and TNF-α production in Sézary syndrome: circumvention by hexameric soluble CD40L

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15

Where have all the T cells gone?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only